Chromatography Resin (PROTEIN A SEPHAROSE)

Description

1. Product Overview

PROTEIN A SEPHAROSE is a high-performance affinity chromatography resin engineered for the capture and purification of monoclonal antibodies (mAbs) and Fc-fusion proteins. Its primary industrial application lies in downstream bioprocessing within biopharmaceutical manufacturing, where it delivers industry-leading binding capacity and purity in a single step. The key value proposition is maximizing mAb yield while minimizing process time and buffer consumption, directly lowering cost of goods sold (COGS) per gram. Strategically, as the global mAb market exceeds $200 billion, consistent and scalable Protein A resin supply is a critical bottleneck—and a competitive differentiator—for CDMOs and innovator biologics firms alike.

2. Key Specifications & Technical Characteristics

• Chemical composition: Highly cross-linked 6% agarose (Sepharose CL-6B) matrix coupled with recombinant Protein A (E. coli-derived), containing four Fc-binding domains

• Purity grade: Protein A ligand purity ≥ 99.5% by HPLC; endotoxin level < 0.5 EU/mL; no animal-derived components (Animal Origin Free – AOF)

• Physical characteristics: Spherical beads, uniform particle size distribution (mean 90 µm), translucent white slurry; settled bed density ~0.2–0.3 g/mL

• Dynamic binding capacity (DBC): ≥ 30 mg human IgG per mL resin at 2-minute residence time (5% breakthrough)

• pH stability: Operational pH 3–10; CIP (clean-in-place) tolerance pH 2–11

• Packaging options: 25 mL, 100 mL, 1 L, 5 L, and 20 L high-density polyethylene (HDPE) bottles; bulk totes (100 L) and pre-packed process-scale columns available

• Shelf life: 5 years when stored unopened at 4–8°C in 20% ethanol; 6 months after first opening under aseptic handling

3. Core Industrial Applications

• Primary industries: Biopharmaceuticals (mAb innovators, biosimilars, CDMOs), vaccine manufacturing (Fc-fusion proteins), academic & industrial R&D labs

• Specific use cases: Capture step for CHO- and E. coli-derived mAbs (IgG1, IgG2, IgG4); purification of Fc-fusion immunoadhesins; removal of host cell proteins (HCPs) and DNA from bioreactor harvests

• Why this product performs better: Unlike silica-based or monolithic resins, PROTEIN A SEPHAROSE exhibits near-zero non-specific binding, enabling >95% HCP clearance in one cycle. Its hydrophilic agarose matrix reduces column backpressure by 40% compared to rigid polymers, allowing 3× higher flow rates for the same bed height.

• Efficiency advantage: Validated over 200 CIP cycles (0.1 M NaOH) without >15% loss in DBC—extending column lifetime and reducing resin replacement costs by 30–50% annually.

4. Competitive Advantages

• Quality consistency: Manufactured under cGMP with ISO 9001:2024 certification; each batch validated by 6 QC tests (including DBC, leakage, and bioburden); lot-to-lot variability <5% CV.

• Supply reliability: Dual-site production (EU + North America) with 6‑month safety stock; proven during global supply chain disruptions (2020–2024) with 100% fulfillment rate.

• Logistics capability: Cold-chain packaging validated for 96-hour ambient thermal stability; real-time temperature loggers included for international shipments.

• Price competitiveness: Tiered pricing based on annual volume (1L–10,000L) with volume discounts up to 35% vs. market average; no licensing surcharge for Protein A ligand.

• Sustainability: Manufacturing uses ≥50% renewable energy; resin can be regenerated and reused for ≥200 cycles, reducing plastic waste by 90% versus single-use alternatives.

• Technical support: Free column packing verification, method development templates (UNICORN™-compatible), and 24‑hour on-call application scientist support included with purchase orders >10L.

5. Commercial & Supply Information

• Minimum Order Quantity (MOQ): BULK 20 MT (20 metric tons of settled resin, equivalent to ~60,000–80,000 L packed bed volume)

• Loading capacity per 20 ft container: 20 MT (single product batch, no mixing) – fitted in FDA-compliant, single-use bioprocess bags inside insulated, refrigerated (4–8°C) ISO containers

• Lead time for MOQ: 10 weeks from purchase order and deposit confirmation (including QC release)

• Payment terms: Letter of Credit (L/C) at sight or 30% deposit / 70% against shipping documents for established buyers